WO1998044933A1 - Preparations polymeres se fixant au phosphate - Google Patents
Preparations polymeres se fixant au phosphate Download PDFInfo
- Publication number
- WO1998044933A1 WO1998044933A1 PCT/JP1998/001536 JP9801536W WO9844933A1 WO 1998044933 A1 WO1998044933 A1 WO 1998044933A1 JP 9801536 W JP9801536 W JP 9801536W WO 9844933 A1 WO9844933 A1 WO 9844933A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phosphate
- binding polymer
- tablet
- less
- particle size
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Definitions
- the present invention relates to a tablet containing a phosphate-binding polymer. More specifically, the phosphate-binding property in which the average particle size is 400 or less, the ratio of the particle size is 500 / zm or less is 90% or more, and the water content is 1 to 14%.
- the present invention relates to a tablet containing a polymer, microcrystalline cellulose and Z or low-substituted hydroxypropylcellulose, and a tablet containing a phosphate-binding polymer exhibiting rapid disintegration dispersibility and phosphate-binding property, and a method for producing the same.
- the phosphate-binding polymer is a non-absorbable polymer having a phosphate adsorption ability, and is useful as a therapeutic agent for hyperphosphatemia due to a decrease in renal function such as chronic renal failure.
- the phosphoric acid-binding polymer is, for example, a cross-linked polymer obtained by cross-linking a polyallylamine with a cross-linking agent such as epichlorohydrin as described in US Pat. No. 5,496,545. It is a known compound known as a polycationic polymer compound comprising quaternary amine.
- Phosphate-binding polymer formulations as therapeutics for hyperphosphatemia are described, for example, in
- No. 5,496,545 discloses that tablets can be prepared by adding various additives including microcrystalline cellulose, but the publication discloses specific examples of the production.
- the present inventors have tried to add various additives to the phosphate-binding polymer obtained by the method described in the official gazette and form tablets by a usual method. It could not be tableted well.
- calcium polystyrene sulfonate preparations known as oral adsorbents [Kalimate (registered trademark), manufactured by Kenken Kagaku Co., Ltd.], sodium polystyrene sulfonate preparations (Gexarate (registered trademark), manufactured by Torii Pharmaceutical Co., Ltd.), adsorption Charcoal preparation [Kremezin (registered trademark), Kureha Chemical Co., Ltd.], cholestyramine preparation [Questran (registered trademark), Bristol * Myers Squibb Co., Ltd.], precipitated calcium carbonate preparation (Emisu Pharmaceutical Co., Ltd.) Dosage forms such as bulk powder, powder or powder It is a filled capsule and no tablet is found.
- Phosphate-binding polymer has the effect of absorbing phosphorus in food by oral administration and excreting it outside the body with feces, thereby reducing the absorption of phosphorus from the gastrointestinal tract and suppressing blood phosphorus concentration.
- One dose 1-2 g is relatively large.
- the phosphate-binding polymer has a property of swelling quickly by reacting with water, it is difficult to take it as it is.
- the dialysis patients who receive the phosphate-binding polymer which is a therapeutic agent for hyperphosphatemia, often have a limited water intake.
- Promising dosage forms include tablets that can be miniaturized by pressurized compression, and preferably coated tablets that can be prevented from disintegration in the mouth and have excellent ingestibility.
- the phosphate binding polymer alone had low tablet hardness due to compression under pressure, and could not be formulated into tablets as it was.
- phosphoric acid-binding polymers have high hygroscopic and swelling properties, it is not possible to use wet granulation and drying by adding a binder solution containing water or alcohol when formulating. could not.
- the present inventors have studied the tableting of a phosphate-binding polymer using various additives described in U.S. Pat.No. 5,496,545, and found that the tablet had sufficient hardness and rapid disintegration. An excellent phosphate-binding polymer-containing tablet exhibiting dispersibility and phosphate binding properties could not be produced.
- the inventors of the present invention have conducted intensive studies in order to solve these problems, and as a result, when the phosphoric acid-binding polymer itself has certain characteristics, when the specific excipient is added, A phosphate-binding polymer tablet with high phosphate-binding polymer content, sufficient hardness, rapid disintegration dispersibility and phosphate-binding properties in the acidic to neutral range
- the present inventors have found that an agent can be produced, and have reached the present invention.
- the average particle size is 400 ⁇ or less, preferably 250 m or less, and the ratio of particle size 500 m or less is 90% or more, preferably the particle size is 300 m or less.
- phosphate-binding polymer with a water content of 90% or more and a water content of 1 to 14%, as well as specific additives such as crystalline cellulose and / or low-substituted hydroxyquinpropyl cellulose. Tablets have excellent properties.
- FIG. 1 is a graph showing the relationship between the water content of a phosphate-binding polymer and tablet hardness in Example 2.
- FIG. 2 is a graph showing the relationship between the water content of the phosphate-binding polymer and the tablet disintegration time in Example 2.
- FIG. 3 is a graph showing the relationship between the water content of the phosphate-binding polymer and the tablet hardness in Example 3.
- FIG. 4 is a graph showing the relationship between the water content of the phosphate-binding polymer and the tablet disintegration time in Example 3.
- FIG. 5 is a graph showing the disintegration characteristics (the relationship between the number of strokes of the disintegration tester and the tablet hardness) of the phosphate-binding polymer preparation in Example 4.
- FIG. 6 is a view showing a phosphate binding profile of the phosphate binding polymer preparation in Example 5.
- the phosphate-binding polymer used in the present invention is, for example, a dried phosphate-binding polymer obtained by the method described in US Pat.
- pulverization is preferably performed so that the ratio of particles having a particle size of 250 m or less and a particle size of 500 m or less is 90% or more, and preferably a ratio of a particle size of 300 m or less is 90% or more.
- the water content may be further adjusted so that the water content is 1 to 14%.
- a polymer obtained by reacting polychloroamine with epichlorohydrin and cross-linking it can be particularly preferably used in the present invention.
- the average particle size of the phosphoric acid-binding polymer is larger than 400 m, it is not preferable because sufficient hardness required for tableting cannot be obtained. Further, if the water content is less than 1%, sufficient hardness required for tableting cannot be obtained, and the tablet surface is easily worn away.If the water content is 14% or more, sufficient hardness is obtained. However, when tableted, it becomes plastically deformable and becomes unsuitable as a pharmaceutical. In order to make tablets with better ingestibility, it is necessary to provide tablets with a hardness of 6KP or more on a tablet hardness tester and a surface strength of 1% or less in weight loss rate in a friability test (100 rotations).
- a tablet having a water content in the range of 1 to 14% may be mentioned.
- the water content of 1 to 14% means that the loss on drying at 105 ° C. for 16 hours is 1 to 14%, and the loss on drying is preferably 2 to 14%.
- the apparatus used for grinding the phosphate-binding polymer is not particularly limited as long as it is a model capable of obtaining a particle diameter of 500 / m or less and the above average particle diameter, for example, an impact-type pulverizer. .
- the phosphoric acid-binding polymer having a desired water content can be obtained by performing the drying step in the production of the phosphate-binding polymer so that the water content is in the range of 1 to 14%.
- the crystalline cellulose used in the present invention is not particularly limited, but those having a loss on drying at 105 ° C for 3 hours of 7% or less can be used.
- Commercial products such as PH101, PH102, PH301 and PH302 can be used alone or in combination.
- the low degree of substitution of the hydroxypropyl cellulose having a low degree of substitution used in the present invention means that the degree of substitution of a hydroxyquinepropoxyl group (1 OC 3 H 6 OH) is 5.0 to 16.0 times.
- the low-substituted hydroxypropylcellulose is, for example, a commercially available product such as LH-11, LH-21 or LH-31 manufactured by Shin-Etsu Chemical Co., Ltd. It is preferable to use them alone or as a mixture.
- the amount of microcrystalline cellulose and / or low-substituted hydroxypropylcellulose added to the phosphate-binding polymer tablet used in the present invention depends on the dose of the phosphate-binding polymer as an oral preparation and the ingestibility of the preparation. It can be set arbitrarily taking into account, for example, in a preferred embodiment, the average particle size is 250 m or less, and the ratio of the particle size is 300 m or less is 90% or more.
- the content of crystalline cellulose or low-substituted hydroxypropylcellulose is preferably at least 10% by weight, more preferably at least 30% by weight, based on the weight of the phosphate-binding polymer having a water content of 1 to 14%.
- the total amount of both added is preferably at least 10% by weight, more preferably at least 30% by weight.
- the upper limit of the amount of microcrystalline cellulose and hydroxy or low-substituted hydroxypropylcellulose is preferably in the range of 50% by weight to 200% by weight.
- phosphate-binding polymers, crystalline cellulose, or low-substituted hydroxyquine propylcell mouths have high frictional properties, so if continuous tableting is performed, the load on the tableting machine due to creaking of the punch will be reduced. It is advisable to add a hardened oil in order to reduce the amount.
- a hardened oil for example, a commercially available product such as Lubriwax (registered trademark) manufactured by Freund Corporation can be used.
- the phosphate-binding polymer tablet of the present invention is produced by adding excipients such as lactose, sucrose, mannitol, etc., and lubricating agents such as magnesium stearate and polyethylene glycol, in addition to crystalline cellulose and / or low-substituted hydroxypropyl cellulose. It can be performed by appropriately adding other conventional additives, flavors, coloring agents, and the like, mixing with the phosphate-binding polymer, and tableting.
- the phosphate-binding polymer tablet of the present invention can be further made into a film tablet having a surface coated with a film.
- Water-soluble films such as hydroxypropyl methylcellulose and acrylic acid copolymer are used for film coating.
- Bases can be used.
- hydroquinpropyl methylcellulose can be preferably used.
- a cross-linking polymerization reaction was performed by adding epichlorohydrin as a cross-linking agent to polyallylamine to form a hydrochloride salt in about 40% of primary amine (81.2 mol 1%) and secondary amine (18.8 mol%).
- the polycationic phosphate-binding polymer was vacuum-dried to obtain a dried powder.
- the dried phosphate-bonded polymer is pulverized using a Fimmill (M5A Fitzpatrick) to obtain a phosphate-bonded polymer containing water (3.6% moisture, particle size 300 / m or less). 7%).
- crystalline cellulose (Avicel PH101 Asahi Kasei) and low-substituted hydroxy lip cellulose (L-HPCLH31, Shin-Etsu Chemical) were used as additives. Either of them is mixed at a ratio of 15 Omg (100% by weight based on the weight of the phosphate-binding polymer). Tablet size ⁇ 1 Omm, tablet weight 30 OmgZ tablet, molding pressure 500 kg, 1000 kg, 1500 kg To obtain tablets.
- lactose 200M DMV
- mannitol mannitol
- methylcellulose trade name: METROSE SM-15 Shin-Etsu Chemical
- Talc Korean Kasei
- hydroquinine propylcellulose HPC-L Nippon Soda
- hydroxypropylmethylcellulose 2910 HPM C TC-15-RW, Shin-Etsu Chemical
- carmellose calcium (trademark ECG-5055) )
- Tablets (no addition) were obtained by static pressure molding using 30 Omg of the crushed powder of the phosphoric acid-binding polymer containing water.
- the hardness of the obtained tablets was measured with a hardness tester (Pharma Test) and the molding pressure was measured.
- the disintegration time was measured using a disintegration tester (wealth, ⁇ 8 shiri (test liquid: water)).
- the water-containing phosphate-binding polymer of Reference Example was dried at 105 ° C. for 16 hours to obtain a dry powder of the phosphate-binding polymer (water content: less than 0.1%). Furthermore, the dried powder of the phosphoric acid-binding polymer is absorbed in a desiccator overnight using an aqueous solution of saturated sodium chloride as a humectant to obtain a phosphoric acid-binding polymer containing 1.1 to 16.4% of water.
- microcrystalline cellulose was mixed as an additive at a ratio of 10 Omg (50% by weight based on the weight of the phosphate-binding polymer) as an additive. Tablets were obtained by static pressure molding under the conditions of 1 Omm, tablet weight of 30 Omg, and molding pressure of 1000 kg.
- Fig. 1 shows the results of the hardness of the obtained tablets measured with a hardness meter
- Fig. 2 shows the results of the disintegration time (test liquid water) measured with a disintegration tester.
- Table 2 Tablet composition Phosphate-binding polymer-Tablet hardness Friability
- the water-containing phosphate-binding polymer of the reference example was converted to 60 mesh (250 / m), 8 Ome sh (180 ⁇ ), 15 Ome sh (106 m), Classify with Ome sh (53 / m) sieve, average particle size 250 zm or more, 180-250 zm, 106-180 m, 53-106 // m, phosphoric acid binding polymer with 53 / m or less I got
- Tablets were prepared by mixing 10 Omg (50% by weight based on the weight of the phosphate-binding polymer) of crystalline cellulose as an additive with 20 Omg of the phosphate-binding polymer having a different average particle size. Tablets were obtained by static pressure molding under the conditions of a diameter of 10 mm, a tablet weight of 300 mg, and a molding pressure of 1 000 kg.
- Fig. 3 shows the results of measuring the hardness of the obtained tablets with a hardness meter
- Fig. 4 shows the results of measuring the disintegration time with a disintegration tester (test liquid water).
- the tablets molded solely with the phosphate-binding polymer did not show sufficient hardness (6 KP or more) with any average particle size.
- the average particle size the higher the hardness. With an average particle size of 250 / m or less, sufficient hardness and rapid disintegration were obtained.
- the tablet obtained was measured with a hardness tester (contester) and showed a tablet hardness of 7.7 KP.
- phosphate-binding polymer uncoated tablet
- hydroxypropylmethylcellulose 2910 HPMC TC-5-MW, Shin-Etsu Chemical
- polyethylene glycol 6000 Nippon Oil & Fat
- acid Titanium chloride A-100 Ishihara Sangyo
- 0.69 mg of talc Film formulation with a coating machine Doriacoater DRC-500, No.1 I got
- the phosphate-binding polymer formulation showed rapid disintegration by adding microcrystalline cellulose in the acidic to neutral range without being affected by the stirring strength (stroke).
- Formulation containing 20 Omg of the phosphate-binding polymer prepared in Example 4 (uncoated tablet and film tablet)
- 4.7 g of sodium chloride, N, N-bis (2 —Hydroxityl) 2-Aminoethanesulfonic acid 21.3 g, potassium dihydrogen phosphate 0.544 g dissolved in water, adjusted to pH 7 and heated to 37 ° C 20 Om 1 was used to measure the phosphate binding ability under the conditions of a paddle rotation speed of 100 rpm.
- the initial value of the test solution was set to 1 for the concentration of phosphoric acid remaining in the test solution over time due to the disintegration of the phosphate-binding polymer and the phosphoric acid adsorption due to the disintegration of the phosphate-binding polymer, and 0 at the end of the adsorption.
- Figure 6 shows the measurement results.
- the phosphate-binding polymer preparation showed rapid phosphate-binding ability by adding microcrystalline cellulose to the preparation.
- the phosphate-binding polymer tablet of the present invention has a high content of the main drug, excellent phosphate binding ability, and exhibits rapid disintegration that is not easily affected by stirring intensity in an acidic to neutral region, and has a gastrointestinal motility. It is an excellent preparation that can reduce the variation in bioavailability due to pH.
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK02025683T DK1304104T3 (da) | 1997-04-04 | 1998-04-03 | Tablet omfattende en phosphatbindende polymer |
EP98911187A EP0997148B1 (en) | 1997-04-04 | 1998-04-03 | Phosphate-binding polymer preparations |
AU65223/98A AU726142B2 (en) | 1997-04-04 | 1998-04-03 | Phosphate-binding polymer preparation |
CA002286003A CA2286003C (en) | 1997-04-04 | 1998-04-03 | Phosphate-binding polymer preparation |
DE69816082T DE69816082T2 (de) | 1997-04-04 | 1998-04-03 | Phosphatbindende polymerzubereitungen |
AT98911187T ATE244013T1 (de) | 1997-04-04 | 1998-04-03 | Phosphatbindende polymerzubereitungen |
US09/381,506 US6383518B1 (en) | 1997-04-04 | 1998-04-03 | Phosphate-binding polymer preparations |
HK00106656A HK1027506A1 (en) | 1997-04-04 | 2000-10-19 | Phosphate-binding polymer preparations |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP8658197 | 1997-04-04 | ||
JP9/86581 | 1997-04-04 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/381,506 A-371-Of-International US6383518B1 (en) | 1997-04-04 | 1998-04-03 | Phosphate-binding polymer preparations |
US10/090,622 Continuation US6696087B2 (en) | 1997-04-04 | 2002-03-06 | Phosphate-binding polymer preparation technical field |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998044933A1 true WO1998044933A1 (fr) | 1998-10-15 |
Family
ID=13890981
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1998/001536 WO1998044933A1 (fr) | 1997-04-04 | 1998-04-03 | Preparations polymeres se fixant au phosphate |
Country Status (16)
Country | Link |
---|---|
US (2) | US6383518B1 (ja) |
EP (2) | EP1304104B1 (ja) |
JP (2) | JP2009173687A (ja) |
KR (1) | KR100456202B1 (ja) |
CN (1) | CN1180782C (ja) |
AT (2) | ATE244013T1 (ja) |
AU (1) | AU726142B2 (ja) |
CA (1) | CA2286003C (ja) |
CY (1) | CY1106823T1 (ja) |
DE (2) | DE69816082T2 (ja) |
DK (1) | DK1304104T3 (ja) |
ES (2) | ES2201463T3 (ja) |
HK (2) | HK1027506A1 (ja) |
PT (1) | PT1304104E (ja) |
TW (1) | TW592727B (ja) |
WO (1) | WO1998044933A1 (ja) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001028527A3 (en) * | 1999-10-19 | 2002-01-03 | Geltex Pharma Inc | Direct compression polymer tablet core |
EP1153940A4 (en) * | 1998-10-12 | 2003-06-25 | Chugai Pharmaceutical Co Ltd | POLYMER COMBINING WITH PHOSPHORIC ACID AND PREPARATION CONTAINING THIS POLYMER |
WO2003053419A1 (fr) * | 2001-12-20 | 2003-07-03 | Chugai Seiyaku Kabushiki Kaisha | Comprimes enrobes et leur procede de production |
US6733780B1 (en) | 1999-10-19 | 2004-05-11 | Genzyme Corporation | Direct compression polymer tablet core |
JP2009526840A (ja) * | 2006-02-14 | 2009-07-23 | テバ ファーマシューティカル インダストリーズ リミティド | 脂肪族アミンポリマーの医薬製剤及びそれらの製造方法 |
EP2545907A1 (en) | 2011-07-15 | 2013-01-16 | Combino Pharm, S.L. | Aqueous wet granulation process for cross-linked polyallylamine polymers |
US8889738B2 (en) | 2006-12-14 | 2014-11-18 | Genzyme Corporation | Amido-amine polymer compositions |
US8900560B2 (en) | 2006-09-29 | 2014-12-02 | Genzyme Corporation | Amide dendrimer compositions |
US8986669B2 (en) | 2005-09-02 | 2015-03-24 | Genzyme Corporation | Method for removing phosphate and polymer used therefore |
US9555056B2 (en) | 2004-11-01 | 2017-01-31 | Genzyme Corporation | Aliphatic amine polymer salts for tableting |
US11147833B2 (en) | 2017-10-16 | 2021-10-19 | Fujifilm Corporation | Therapeutic agent for hyperphosphatemia |
US11186685B2 (en) | 2016-12-28 | 2021-11-30 | Fujifilm Corporation | Emulsion of nitrogen atom-containing polymer or salt thereof, production method therefor, and production method for particles |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9720061D0 (en) | 1997-09-19 | 1997-11-19 | Crosfield Joseph & Sons | Metal compounds as phosphate binders |
JP3718341B2 (ja) * | 1998-05-12 | 2005-11-24 | 信越化学工業株式会社 | 低置換度ヒドロキシプロピルセルロースとその製造方法 |
US20020054903A1 (en) * | 1999-10-19 | 2002-05-09 | Joseph Tyler | Direct compression polymer tablet core |
US6680069B1 (en) | 1999-11-09 | 2004-01-20 | Shin-Etsu Chemical Co., Ltd. | Low-substituted hydroxypropyl cellulose and process for manufacturing the same |
JP3552160B2 (ja) | 2000-01-14 | 2004-08-11 | 信越化学工業株式会社 | 低置換度ヒドロキシプロピルセルロース粒子の形成方法 |
WO2002066543A1 (en) | 2001-02-16 | 2002-08-29 | Genzyme Corporation | Method of drying a material having a cohesive phase |
WO2002085379A1 (en) * | 2001-04-18 | 2002-10-31 | Geltex Pharmaceuticals, Inc. | Method for improving vascular access in patients with vascular shunts |
NZ528831A (en) | 2001-04-18 | 2005-07-29 | Genzyme Corp | Method for lowering serum glucose |
NZ528829A (en) | 2001-04-18 | 2006-06-30 | Genzyme Corp | Low salt forms of polyallylamine |
FR2827771B1 (fr) * | 2001-07-25 | 2003-10-24 | Apis Spheromont | Formulation et procede de preparation de spheroides pouvant etre fortement titres et a dispersion rapide |
US6600011B2 (en) | 2001-10-09 | 2003-07-29 | Genzyme Corporation | Process for purification and drying of polymer hydrogels |
US7335795B2 (en) | 2004-03-22 | 2008-02-26 | Ilypsa, Inc. | Crosslinked amine polymers |
US7449605B2 (en) * | 2003-11-03 | 2008-11-11 | Ilypsa, Inc. | Crosslinked amine polymers |
US7385012B2 (en) * | 2003-11-03 | 2008-06-10 | Ilypsa, Inc. | Polyamine polymers |
US7608674B2 (en) | 2003-11-03 | 2009-10-27 | Ilypsa, Inc. | Pharmaceutical compositions comprising cross-linked small molecule amine polymers |
US7767768B2 (en) | 2003-11-03 | 2010-08-03 | Ilypsa, Inc. | Crosslinked amine polymers |
US7459502B2 (en) | 2003-11-03 | 2008-12-02 | Ilypsa, Inc. | Pharmaceutical compositions comprising crosslinked polyamine polymers |
US20060177415A1 (en) * | 2004-11-01 | 2006-08-10 | Burke Steven K | Once a day formulation for phosphate binders |
CA2601236A1 (en) * | 2005-03-16 | 2006-09-21 | Usv Limited | An improved process for the preparation of crosslinked polyallylamine polymer |
JP5595660B2 (ja) | 2005-09-15 | 2014-09-24 | ジェンザイム コーポレーション | アミンポリマー用サシェ製剤 |
GB0601899D0 (en) * | 2006-01-31 | 2006-03-08 | Ineos Silicas Ltd | Compositions |
MY157620A (en) | 2006-01-31 | 2016-06-30 | Cytochroma Dev Inc | A granular material of a solid water-soluble mixed metal compound capable of binding phosphate |
PL1818048T3 (pl) * | 2006-02-14 | 2009-06-30 | Teva Pharma | Formulacje farmaceutyczne zawierające polimery amin alifatycznych oraz sposoby ich wytwarzania |
EP2016114A2 (en) * | 2006-05-05 | 2009-01-21 | Genzyme Corporation | Amine condensation polymers as phosphate sequestrants |
AU2007275711A1 (en) * | 2006-07-18 | 2008-01-24 | Genzyme Corporation | Amine dendrimers |
US7964182B2 (en) * | 2006-09-01 | 2011-06-21 | USV, Ltd | Pharmaceutical compositions comprising phosphate-binding polymer |
BRPI0717008A2 (pt) * | 2006-09-01 | 2014-01-21 | Usv Ltd | Processo para o preparo de cloridrato de sevelamer e formulação do mesmo |
US20100129309A1 (en) * | 2007-02-23 | 2010-05-27 | Dhal Pradeep K | Amine polymer compositions |
WO2008109095A1 (en) * | 2007-03-08 | 2008-09-12 | Genzyme Corporation | Sulfone polymer compositions |
JP2010525061A (ja) * | 2007-04-27 | 2010-07-22 | ゲンズイメ コーポレーション | アミドアミンデンドリマー組成物 |
GB0714670D0 (en) | 2007-07-27 | 2007-09-05 | Ineos Healthcare Ltd | Use |
WO2009034540A1 (en) * | 2007-09-11 | 2009-03-19 | Ranbaxy Laboratories Limited | Pharmaceutical composition of sevelamer |
GB0720220D0 (en) | 2007-10-16 | 2007-11-28 | Ineos Healthcare Ltd | Compound |
JP2011506449A (ja) * | 2007-12-14 | 2011-03-03 | ジェンザイム コーポレーション | コーティング医薬組成物 |
WO2009154747A1 (en) * | 2008-06-20 | 2009-12-23 | Genzyme Corporation | Pharmaceutical compositions |
DE102008030046A1 (de) | 2008-06-25 | 2009-12-31 | Ratiopharm Gmbh | Kompaktiertes Polyallylamin-Polymer |
US20110081413A1 (en) * | 2009-01-22 | 2011-04-07 | Ashok Omray | Pharmaceutical Compositions Comprising Phosphate-Binding Polymer |
US20100330175A1 (en) * | 2009-06-24 | 2010-12-30 | Jobdevairakkam Christopher N | Cross-linked polyallylamine tablet core |
WO2010149794A2 (en) | 2009-06-26 | 2010-12-29 | Combino Pharm, S.L. | Novel pharmaceutical composition comprising poly (allylamin-co-n,n'-diallyl- 1,3-diamino-2-hydroxypropane) |
GB0913525D0 (en) | 2009-08-03 | 2009-09-16 | Ineos Healthcare Ltd | Method |
EA024699B1 (ru) * | 2009-10-22 | 2016-10-31 | Синтон Б. В. | Фармацевтическая таблетка с немедленным высвобождением, содержащая севеламера карбонат |
GB201001779D0 (en) | 2010-02-04 | 2010-03-24 | Ineos Healthcare Ltd | Composition |
MA41202A (fr) | 2014-12-18 | 2017-10-24 | Genzyme Corp | Copolymères polydiallymine réticulé pour le traitement du diabète de type 2 |
WO2016135065A1 (en) * | 2015-02-23 | 2016-09-01 | Amneal Pharmaceuticals Company Gmbh | Process for granulating sevelamer carbonate |
EP3698798A4 (en) * | 2017-10-16 | 2020-12-23 | FUJIFILM Corporation | AGENTS FOR TREATMENT OF HYPERPHOSPHATEMIA AND PARTICLES |
JP2019182818A (ja) * | 2018-04-17 | 2019-10-24 | ライオン株式会社 | 舌苔除去用の口腔内崩壊錠及び舌苔除去方法 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4631305A (en) * | 1985-03-22 | 1986-12-23 | The Upjohn Company | Polymeric material as a disintegrant in a compressed tablet |
JPS63253027A (ja) * | 1986-12-30 | 1988-10-20 | アメリカン・サイアナミド・カンパニー | ポリカルボフイル含有組成物 |
JPH02286621A (ja) * | 1989-04-26 | 1990-11-26 | Mitsubishi Kasei Corp | 経口コレステロール低下剤 |
JPH0413627A (ja) * | 1990-04-27 | 1992-01-17 | Mitsubishi Kasei Corp | 経口コレステロール低下剤 |
JPH05246861A (ja) * | 1990-11-29 | 1993-09-24 | Hokuriku Seiyaku Co Ltd | ポリカルボフィルカルシウム含有製剤 |
JPH06157325A (ja) * | 1992-11-30 | 1994-06-03 | Mitsubishi Kasei Corp | 経口コレステロール低下剤 |
US5496545A (en) * | 1993-08-11 | 1996-03-05 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
JPH08198761A (ja) * | 1995-01-24 | 1996-08-06 | Hokuriku Seiyaku Co Ltd | ポリカルボフィルカルシウム含有製剤 |
WO1997004789A1 (fr) * | 1995-08-02 | 1997-02-13 | Hisamitsu Pharmaceutical Co., Inc. | Comprimes contenant une resine echangeuse d'anions |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6090243A (ja) | 1983-10-25 | 1985-05-21 | Nitto Boseki Co Ltd | 小球状モノアリルアミン橋かけ重合体の製造方法 |
US4956182A (en) * | 1989-03-16 | 1990-09-11 | Bristol-Myers Company | Direct compression cholestyramine tablet and solvent-free coating therefor |
TW272942B (ja) | 1993-02-10 | 1996-03-21 | Takeda Pharm Industry Co Ltd | |
US5667775A (en) * | 1993-08-11 | 1997-09-16 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
WO1996021454A1 (en) * | 1995-01-12 | 1996-07-18 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
JP3389493B2 (ja) * | 1997-04-04 | 2003-03-24 | 中外製薬株式会社 | リン酸結合性ポリマー製剤 |
-
1998
- 1998-03-19 TW TW087104092A patent/TW592727B/zh not_active IP Right Cessation
- 1998-04-03 PT PT02025683T patent/PT1304104E/pt unknown
- 1998-04-03 CA CA002286003A patent/CA2286003C/en not_active Expired - Lifetime
- 1998-04-03 ES ES98911187T patent/ES2201463T3/es not_active Expired - Lifetime
- 1998-04-03 EP EP02025683A patent/EP1304104B1/en not_active Expired - Lifetime
- 1998-04-03 CN CNB988046245A patent/CN1180782C/zh not_active Expired - Lifetime
- 1998-04-03 ES ES02025683T patent/ES2287215T3/es not_active Expired - Lifetime
- 1998-04-03 DE DE69816082T patent/DE69816082T2/de not_active Expired - Lifetime
- 1998-04-03 US US09/381,506 patent/US6383518B1/en not_active Expired - Lifetime
- 1998-04-03 AT AT98911187T patent/ATE244013T1/de active
- 1998-04-03 KR KR10-1999-7009058A patent/KR100456202B1/ko not_active IP Right Cessation
- 1998-04-03 WO PCT/JP1998/001536 patent/WO1998044933A1/ja active IP Right Grant
- 1998-04-03 DE DE69837945T patent/DE69837945T2/de not_active Expired - Lifetime
- 1998-04-03 AT AT02025683T patent/ATE364377T1/de active
- 1998-04-03 AU AU65223/98A patent/AU726142B2/en not_active Expired
- 1998-04-03 EP EP98911187A patent/EP0997148B1/en not_active Expired - Lifetime
- 1998-04-03 DK DK02025683T patent/DK1304104T3/da active
-
2000
- 2000-10-19 HK HK00106656A patent/HK1027506A1/xx not_active IP Right Cessation
-
2002
- 2002-03-06 US US10/090,622 patent/US6696087B2/en not_active Expired - Lifetime
-
2003
- 2003-10-15 HK HK03107427A patent/HK1055387A1/xx not_active IP Right Cessation
-
2007
- 2007-08-23 CY CY20071101107T patent/CY1106823T1/el unknown
-
2009
- 2009-05-15 JP JP2009118371A patent/JP2009173687A/ja not_active Withdrawn
-
2012
- 2012-10-18 JP JP2012230662A patent/JP5681156B2/ja not_active Expired - Fee Related
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4631305A (en) * | 1985-03-22 | 1986-12-23 | The Upjohn Company | Polymeric material as a disintegrant in a compressed tablet |
JPS63253027A (ja) * | 1986-12-30 | 1988-10-20 | アメリカン・サイアナミド・カンパニー | ポリカルボフイル含有組成物 |
JPH02286621A (ja) * | 1989-04-26 | 1990-11-26 | Mitsubishi Kasei Corp | 経口コレステロール低下剤 |
JPH0413627A (ja) * | 1990-04-27 | 1992-01-17 | Mitsubishi Kasei Corp | 経口コレステロール低下剤 |
JPH05246861A (ja) * | 1990-11-29 | 1993-09-24 | Hokuriku Seiyaku Co Ltd | ポリカルボフィルカルシウム含有製剤 |
JPH06157325A (ja) * | 1992-11-30 | 1994-06-03 | Mitsubishi Kasei Corp | 経口コレステロール低下剤 |
US5496545A (en) * | 1993-08-11 | 1996-03-05 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
JPH08198761A (ja) * | 1995-01-24 | 1996-08-06 | Hokuriku Seiyaku Co Ltd | ポリカルボフィルカルシウム含有製剤 |
WO1997004789A1 (fr) * | 1995-08-02 | 1997-02-13 | Hisamitsu Pharmaceutical Co., Inc. | Comprimes contenant une resine echangeuse d'anions |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1153940A4 (en) * | 1998-10-12 | 2003-06-25 | Chugai Pharmaceutical Co Ltd | POLYMER COMBINING WITH PHOSPHORIC ACID AND PREPARATION CONTAINING THIS POLYMER |
US6733780B1 (en) | 1999-10-19 | 2004-05-11 | Genzyme Corporation | Direct compression polymer tablet core |
WO2001028527A3 (en) * | 1999-10-19 | 2002-01-03 | Geltex Pharma Inc | Direct compression polymer tablet core |
US20120322894A1 (en) * | 1999-10-19 | 2012-12-20 | Genzyme Corporation | Direct Compression Polymer Tablet Core |
US9931358B2 (en) | 1999-10-19 | 2018-04-03 | Genzyme Corporation | Direct compression polymer tablet core |
WO2003053419A1 (fr) * | 2001-12-20 | 2003-07-03 | Chugai Seiyaku Kabushiki Kaisha | Comprimes enrobes et leur procede de production |
US9895315B2 (en) | 2004-11-01 | 2018-02-20 | Genzyme Corporation | Aliphatic amine polymer salts for tableting |
US9555056B2 (en) | 2004-11-01 | 2017-01-31 | Genzyme Corporation | Aliphatic amine polymer salts for tableting |
US8986669B2 (en) | 2005-09-02 | 2015-03-24 | Genzyme Corporation | Method for removing phosphate and polymer used therefore |
JP2009526840A (ja) * | 2006-02-14 | 2009-07-23 | テバ ファーマシューティカル インダストリーズ リミティド | 脂肪族アミンポリマーの医薬製剤及びそれらの製造方法 |
US9066972B2 (en) | 2006-09-29 | 2015-06-30 | Genzyme Corporation | Amide dendrimer compositions |
US8900560B2 (en) | 2006-09-29 | 2014-12-02 | Genzyme Corporation | Amide dendrimer compositions |
US8889738B2 (en) | 2006-12-14 | 2014-11-18 | Genzyme Corporation | Amido-amine polymer compositions |
EP2545907A1 (en) | 2011-07-15 | 2013-01-16 | Combino Pharm, S.L. | Aqueous wet granulation process for cross-linked polyallylamine polymers |
US11186685B2 (en) | 2016-12-28 | 2021-11-30 | Fujifilm Corporation | Emulsion of nitrogen atom-containing polymer or salt thereof, production method therefor, and production method for particles |
US11147833B2 (en) | 2017-10-16 | 2021-10-19 | Fujifilm Corporation | Therapeutic agent for hyperphosphatemia |
Also Published As
Publication number | Publication date |
---|---|
CN1254287A (zh) | 2000-05-24 |
EP1304104A3 (en) | 2003-11-12 |
TW592727B (en) | 2004-06-21 |
EP0997148B1 (en) | 2003-07-02 |
PT1304104E (pt) | 2007-07-27 |
US6696087B2 (en) | 2004-02-24 |
KR20010005980A (ko) | 2001-01-15 |
CY1106823T1 (el) | 2012-05-23 |
DE69837945T2 (de) | 2008-02-21 |
JP5681156B2 (ja) | 2015-03-04 |
CN1180782C (zh) | 2004-12-22 |
EP1304104B1 (en) | 2007-06-13 |
ES2287215T3 (es) | 2007-12-16 |
EP1304104A2 (en) | 2003-04-23 |
ATE244013T1 (de) | 2003-07-15 |
ES2201463T3 (es) | 2004-03-16 |
DE69816082D1 (de) | 2003-08-07 |
HK1027506A1 (en) | 2001-01-19 |
KR100456202B1 (ko) | 2004-11-09 |
AU6522398A (en) | 1998-10-30 |
JP2013010803A (ja) | 2013-01-17 |
HK1055387A1 (en) | 2004-01-09 |
ATE364377T1 (de) | 2007-07-15 |
CA2286003C (en) | 2007-06-05 |
JP2009173687A (ja) | 2009-08-06 |
DK1304104T3 (da) | 2007-07-16 |
AU726142B2 (en) | 2000-11-02 |
EP0997148A1 (en) | 2000-05-03 |
DE69837945D1 (de) | 2007-07-26 |
DE69816082T2 (de) | 2004-04-15 |
CA2286003A1 (en) | 1998-10-15 |
US6383518B1 (en) | 2002-05-07 |
US20020122786A1 (en) | 2002-09-05 |
EP0997148A4 (en) | 2000-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998044933A1 (fr) | Preparations polymeres se fixant au phosphate | |
JP3302682B2 (ja) | リン酸結合性ポリマーを使用した錠剤 | |
JP4942271B2 (ja) | 直接圧縮ポリマー錠剤コア | |
JPH0415208B2 (ja) | ||
JPH059413B2 (ja) | ||
EP2010159A1 (en) | Fast release paracetamol tablets | |
CN111840239B (zh) | 一种普瑞巴林缓释制剂 | |
JP2686215B2 (ja) | 徐放性錠剤 | |
JP3389493B2 (ja) | リン酸結合性ポリマー製剤 | |
JP4010585B2 (ja) | 陰イオン交換樹脂を含有する錠剤 | |
TW201306881A (zh) | 緩釋對乙醯胺基酚調配物 | |
JP3363143B2 (ja) | リン酸結合性ポリマー粒子 | |
FI119353B (fi) | Hitaasti vapauttava täyteaine | |
JP4749649B2 (ja) | リン酸結合性ポリマー | |
WO2005018618A1 (en) | Formulation of stable for moisture absorption and quickly dissolved tablet containing cefuroxime axetil and it's manufacturing process | |
JP2003183168A (ja) | リン酸結合性ポリマー含有製剤 | |
JP2002265371A (ja) | リン酸結合性ポリマー製剤 | |
Aucamp | Assessment of the tableting properties of chitosan through wet granulation and direct compression formulations | |
Lakshmi | Formulation and Evaluation of Glucosamine Hydrochloride Sustained Releasematrix Tablet |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 98804624.5 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS KE KG KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09381506 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 65223/98 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019997009058 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2286003 Country of ref document: CA Ref document number: 2286003 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998911187 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1998911187 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019997009058 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 65223/98 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998911187 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1019997009058 Country of ref document: KR |